Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials

UCLA's Jonsson Comprehensive Cancer Center

UCLA's Jonsson Comprehensive Cancer Center
JCCC: A Comprehensive Cancer Center
JCCC Member Directory
Calendar
Contact Us
Map and Directions to JCCC
Social Media
Connect via Mobile
Privacy Practices
 
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Roger Lo, M.D., Ph.D.
Roger Lo, M.D., Ph.D.

Specialty:

Dermatology

General Information:

Gender:
Male
Language(s):
English

Affiliation(s):

Assistant Professor, Department of Medicine, Dermatology
Assistant Professor, Department of Molecular and Medical Pharmacology
Member, JCCC Signal Transduction and Therapeutics Program Area

Hospital Affiliation(s):

Santa Monica-UCLA Medical Center and Orthopaedic Hospital
Ronald Reagan UCLA Medical Center

Education:

Residency:
Dermatology, UCLA, 2003 - 2006
Internship:
Medicine, St. Vincent's Medical Center, 2002 - 2003
Medical Degree:
M.D., Cornell University Medical College, 2002
Degree:
Ph.D., Tri-Institutional Program (Cornell University Medical College, Rockefeller University, and Sloan-Kettering Institute), 2002

Certification(s):

Medical Board Certification(s):
Dermatology, American Board of Dermatology, 2007

Contact Information:

General Dermatology
(310) 917-3376 Information and referral
(310) 267-4433 Prescription refills
Dermatology Surgery Clinic
(310) 825-6911 Information and referral
(310) 267-4472 Prescription refills
Phone:
(310) 825-5420
Email:
rlo@mednet.ucla.edu

Scientific Interest(s):

Dr. Roger Lo’s laboratory is focused on melanoma research in three thematic areas:
  • Discovering somatically mutated genes in melanoma using exon capture and next-generation sequencing and studying these genes in the pathogenesis of melanoma.
  • Dissecting oncogene co-dependent survival networks in melanoma using V600EB-RAF as a prototypic melanoma oncogene and siRNA library as a discovery tool.
  • Understanding the mechanisms of primary and acquired resistance to targeted therapies (including B-RAF inhibitors) using integrated genomic technologies.

Selected Cancer-Related Publications:

Shi H, Moriceau G, Kong X, Lee MK, Lee H, Koya RC, Ng C, Chodon T, Scolyer RA, Dahlman KB, Sosman JA, Kefford RF, Long GV, Nelson SF, Ribas A, Lo RS. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun. 2012 Mar 6;3:724. doi: 10.1038/ncomms1727.

Shi H, Moriceau G, Kong X, Koya R, Nazarian R, Bacchiocchi A, Dahlman K, Sosman JA, Halaban R, Kefford R, Long GV, Ribas A, Lo RS. Pre-existing MEK1 exon 3 mutations in V600E/KB-RAF melanomas do not confer resistance to B-RAF inhibitors. Cancer Discovery, epub April 1, 2012; doi:10.1158/2159-8290.CD-12-0022.

Shi H, Kong X, Ribas A, Lo RS. Combinatorial Treatments That Overcome PDGFR{beta}-Driven Resistance of Melanoma Cells to V600EB-RAF Inhibition. Cancer Res. 2011 Aug 1;71(15):5067-74.

Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, Salton M, Dahlman KB, Tadi M, Wargo JA, Flaherty KT, Kelley MC, Misteli T, Chapman PB, Sosman JA, Graeber TG, Ribas A, Lo RS, Rosen N, Solit DB. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011 Nov 23;480(7377):387-90. doi: 10.1038/nature10662.

Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010 Dec 16;468(7326):973-7. Epub 2010 Nov 24.

In the News: